Insulin glargine 300 U/mL and insulin degludec: A review of the current evidence comparing these two second-generation basal insulin analogues.
Alice Y Y ChengTimothy S BaileyEsmeralda CastelblancoRonan RousselPublished in: Diabetes/metabolism research and reviews (2020)
For most people with type 2 diabetes (T2D), treatment intensification with the addition of basal insulin therapy is required to maintain glycaemic control. However, this often does not happen in real-life practice promoting the development of long-term diabetes-related complications. The second-generation basal insulin analogues glargine 300 U/mL (Gla-300) and degludec (IDeg) provide pharmacokinetic and pharmacodynamic improvements that may allow them to be more effective in appropriately managing diabetes compared with first-generation basal insulin analogues. Both Gla-300 and IDeg have been extensively studied vs the first-generation basal insulin glargine 100 U/mL, demonstrating comparable efficacy in terms of glycaemic control, and a lower risk of hypoglycaemia. The BRIGHT randomized controlled trial is the first direct comparison of the efficacy and safety profiles of Gla-300 and IDeg in patients with T2D. Moreover, real-world data have been used to assess the effectiveness of these basal insulins during routine clinical practice. Further research is required to determine if the properties of Gla-300 and IDeg may lead to improvements in healthcare-related costs and the quality of life of patients, which are important factors for informing clinical decisions.
Keyphrases
- type diabetes
- glycemic control
- randomized controlled trial
- healthcare
- clinical practice
- cardiovascular disease
- insulin resistance
- end stage renal disease
- systematic review
- primary care
- newly diagnosed
- weight loss
- multidrug resistant
- peritoneal dialysis
- stem cells
- skeletal muscle
- patient reported outcomes
- machine learning
- health information
- cell therapy
- big data
- combination therapy